Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 11/2016

Open Access 01-11-2016 | Review

The biology of extracellular vesicles with focus on platelet microparticles and their role in cancer development and progression

Authors: M. Żmigrodzka, M. Guzera, A. Miśkiewicz, D. Jagielski, A. Winnicka

Published in: Tumor Biology | Issue 11/2016

Login to get access

Abstract

Extracellular vesicles (EVs) are a heterogeneous group of structures which can be classified into smaller in size and relatively homogenous exosomes (EXSMs)—spherical fragments of lipid bilayers from inner cell compartments—and bigger in size ectosomes (ECSMs)—a direct consequence of cell-membrane blebbing. EVs can be found in body fluids of healthy individuals. Their number increases in cancer and other pathological conditions. EVs can originate from various cell types, including leukocytes, erythrocytes, thrombocytes, and neoplastic cells. Platelet microparticles (PMPs) are the most abundant population of EVs in blood. It is well documented that PMPs, being a crucial element of EVs signaling, are involved in tumor growth, metastasis, and angiogenesis and may participate in the development of multidrug resistance by tumor cells. The aim of this review is to present the role of PMPs in carcinogenesis. The biology and functions of PMPs with a particular emphasis on the most recent scientific reports on EV properties are also characterized.
Literature
1.
Frydrychowicz M, Kolecka-Bednarczyk A, Madejczyk M, Yasar S, Dworacki G. Exosomes—structure, biogenesis and biological role in non-small-cell lung cancer. Scand J Immunol. 2015;81:2–10.PubMedCrossRef
2.
Freyssinet JM, Toti F. Formation of procoagulant microparticles and properties. Thromb Res. 2010;125:46–8.CrossRef
3.
Flumenhaft R. Formation and fate of platelet microparticles. Blood Cell Mol Dis. 2006;36:182–7.CrossRef
4.
Horstman LL, Ahn . Platelet microparticles: a wide-angle perspective 1999;30:111–142.
5.
6.
Joop K, Berckmans RJ, Nieuwland R, et al. Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. Thromb Haemost. 2001;85:810–20.PubMed
7.
Berckmans RJ, Neiuwland R, Boing AN, et al. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost. 2001;85:639–46.PubMed
8.
Doeuvre L, Plawinski L, Toti F, Angles-Cano E. Cell-derived microparticles: a new challenge in neuroscience. J Neurochem. 2009;110:457–68.PubMedCrossRef
9.
Tan KT, Lip GY. The potential role of platelet microparticles in atherosclerosis. Thromb Haemost. 2005;94:488–92.PubMed
10.
Kim HK, Song KS, Chung JH, Lee KR, Lee SN. Platelet microparticles induce angiogenesis in vitro. Br J Haematol. 2004;124:376–84.PubMedCrossRef
11.
Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia. 2006;20:1487–95.PubMedCrossRef
12.
Hugel B, Martinez MC, Kunzelmann C, Freyssinet JM. Membrane microparticles: two sides of the coin. Physiology. 2005;20:22–7.PubMedCrossRef
13.
Beaudoin AR, Grondin G. Shedding of vesicular material from the cell surface of eukaryotic cells: different cellular phenomena. Bioch Biophys Acta 1991;1071: 203.
14.
Fevrier B, Raposo G. Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr Opin Cell Biol. 2004;16:415–21.PubMedCrossRef
15.
16.
17.
Lee TH, D’Asti E, Magnus N, Al-Nedawi K, Meehan B, Rak J. Microvesicles as mediators of intercellular communication in cancer—the emerging science of cellular ‘debris. Semin Immunopathol. 2011;33:455–67.PubMedCrossRef
18.
Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, Rak J. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol. 2008;10:619–24.PubMedCrossRef
19.
Vlassov AV, Magdaleno S, Setterquist R, Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta. 2012.
20.
Simpson RJ, Lim JW, Moritz RL, Mathivanan S. Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics. 2009;6:267–83.PubMedCrossRef
21.
Bobrie A, Colombo M, Raposo G, Théry C. Exosome secretion: molecular mechanism and roles in immune responses. Traffic. 2011;12:1659–68.PubMedCrossRef
22.
Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes. J Biol Chem. 1987;262:9412–20.PubMed
23.
Clayton A, Turkes A, Navabi H, Mason MD, Tabi Z. Induction of heat shock proteins in B-cell exosomes. J Cell Sci. 2005;118:3631–8.PubMedCrossRef
24.
Ge R, Tan E, Sharghi-Namini S, Asada HH. Exosomes in cancer microenvironment and beyond: have we overlooked these extracellular messengers? Cancer Microenviron. 2012;5:323–32.PubMedPubMedCentralCrossRef
25.
Lotvall J, Valadi H. Cell to cell signalling via exosomes through esRNA. Cell Adhes Migr. 2007;1:156–8.CrossRef
26.
Mignot G, Roux S, Thery C, S_egura E, Zitvogel L. Prospects for exosomes in immunotherapy of cancer. J Cell Mol Med. 2006;10:376–88.PubMedCrossRef
27.
Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2:569–79.PubMed
28.
Chaput N, Théry C. Exosomes: immune properties and potential clinical implementations. Semin Immunopathol. 2011;33:419–40.PubMedCrossRef
29.
Diamant M, Tushuizen ME, Sturk A, Nieuwland R. Cellular microparticles: new players in the field of vascular disease? Eur J Clin Investig. 2004;34:392–401.CrossRef
30.
Kharaziha P, Ceder S, Li Q, Panaretakis T. Tumor cell-derived exosomes: a message in a bottle. Biochim Biophys Acta. 2012.
31.
Reiners KS, Dassler J, Coch CH, Pogge von Strandmann E. Role of exosomes released by dendritic cells and/or by tumor targets: regulation of NK cell plasticity. Front Immunol. 2014.
32.
33.
Gelderman MP, Simak J. Flow cytmometric analysis of cell membrane microparticles. Methods Mol Biol. 2008;484:79–93.PubMedCrossRef
34.
Piccin A, Murphy WG, Smith OP. Circulating microparticles: pathophysiology and clinical implications. Blood Rev. 2007;21:157–71.PubMedCrossRef
35.
Falanga A, Tartari CA, Marchetti M. Microparticles in tumor progression. Thromb Res. 2012;129(Supplement 1):132–6.CrossRef
36.
Flaumenhaft R, Dilks JR, Richardson J, Alden E, Patel-Hett SR, Battinelli E, et al. Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived microparticles. Blood. 2009;113:1112–21.PubMedPubMedCentralCrossRef
37.
Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more. Trends Cell Biol. 2009;19:43–51.PubMedCrossRef
38.
39.
Biscoe TJ, Stehbens WE. Ultrastructure of the carotid body. J Cell Biol. 196(30):563–78.
40.
Combes V, Simon AC, Grau GE, Arnoux D, Camoin L, Sabatier F, Mutin M, Sanmarco M, Sampol J, Dignat-George F. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest. 1999;104:93–102.PubMedPubMedCentralCrossRef
41.
Bianco F, Perrotta C, Novellino L, Francolini M, Riganti L, Menna E, Saglietti L, Schuchman EH, Furlan R, Clementi E, Matteoli M, Verderio C. Acid sphingomyelinase activity triggers microparticle release from glial cells. EMBO J. 2009;28:1043–54.PubMedPubMedCentralCrossRef
42.
Simons M, Raposo G. Exosomes—vesicular carriers for intercellular communication. Curr Opin Cell Biol. 2009;21:575–81.PubMedCrossRef
43.
Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A. Cell-derived microparticles in haemostasis and vascular medicine. Tromb Haemost. 2009;101:439–45143.
44.
Morel O, Morel N, Jesel L, Freyssinet JM, Toti F. Microparticles: a critical component in the nexus between inflammation, immunity, and thrombosis. Semin Immunopathol. 2011;33:469–86.PubMedCrossRef
45.
Lhermusier T, Chap H, Payrastre B. Platelet membrane phospholipid asymmetry: from the characterization of a scramblase activity to the identification of an essential protein mutated in Scott syndrome. J Thromb Haemost. 2011;9:1883–91.PubMedCrossRef
46.
47.
Jimenez JJ, Jy W, Mauro LM, Soderland C, Horstman LL, Ahn YS. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res. 2003;109:175–80.PubMedCrossRef
48.
Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol. 1967;13:269–88.PubMedCrossRef
49.
Basse F, Gaffet P, Bienvenue A. Correlation between inhibition of cytoskeleton proteolysis and anti-vesiculation effect of calpeptin during A23187-induced activation of human platelets: are vesicles shed by filopod fragmentation? Biochim Biophys Acta. 1994;1190:217–24.PubMedCrossRef
50.
Fox JE, Austin CD, Boyles JK, Steffen PK. Role of the membranę skeleton in preventing the shedding of procoagulant-rich microvesicles from the platelet plasma membrane. J Cell Biol. 1990;111:483–93.PubMedCrossRef
51.
Shcherbina A, Bretscher A, Kenney DM, E. R-O′D. Moesin, the major ERM protein of lymphocytes and platelets, differs from ezrin in its insensitivity to calpain. FEBS Lett. 1999;443:31–6.PubMedCrossRef
52.
Weidmer T, Sanford JS, Cunningham M, Sims PJ. Role of calcium and calpain in complement-induced vesiculation of the platelet plasma membrane and in the exposure of the platelet factor Va receptor. Biochemistry. 1990;29:623–32.CrossRef
53.
Pasquet JM, Dachary-Prigent J, Nurden AT. Microvesicle release is associated with extensive protein tyrosine dephosphorylation in platelets stimulated by A23187 or a mixture of thrombin and collagen. Biochem J. 1998;333:591–9.PubMedPubMedCentralCrossRef
54.
Wiedmer T, Sims PJ. Participation of protein kinases in complement C5b-9-induced shedding of platelet plasma membrane vesicles. Blood. 1991;78:2880–6.PubMed
55.
Rand ML, Wang H, Bang KW, Packham MA, Freedman J. Rapid clearance of procoagulant platelet-derived microparticles from the circulation of rabbits. J Thromb Haemost. 2006;4:1621–3.PubMedCrossRef
56.
Bode AP, Miller DT. Analysis of platelet factor 3 in platelet concentrates stored for transfusion. Vox Sang. 1986;51:299–305.PubMedCrossRef
57.
Mathivanan S, Simpson RJ. ExoCarta: a compendium of exosomal proteins and RNA. Proteomics. 2009;9:4997–5000.PubMedCrossRef
58.
Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010;101:2087–92.PubMedCrossRef
59.
Théry C, Boussac M, Véron P, Ricciardi-Castagnoli P, Raposo G, Garin J, Amigorena S. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol. 2001;166:7309–18.PubMedCrossRef
60.
Peche H, Heslan M, Usal C, Amigorena S, Cuturi MC. Presentation of donor major histocompatibility complex antigens by bone marrow dendritic cell-derived exosomes modulates allograft rejection. Transplantation. 2003;76:1503–10.PubMedCrossRef
61.
Wubbolts R, Leckie RS, Veenhuizen PT, Schwarzmann G, Möbius W, Hoernschemeyer J, Slot JW, Geuze HJ, Stoorvogel W. Proteomic and biochemical analyses of human B cell derived exosomes. Potential implications for their function and multivesicular body formation. J Biol Chem. 2003;278:10963–72.PubMedCrossRef
62.
Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654–9.PubMedCrossRef
63.
George JN, Pickett EB, Saucerman S, McEver RP, Kuniki TJ, Kieffer N, Newman PJ. Platelet surface glycoproteins: studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest. 1986;78:340–8.PubMedPubMedCentralCrossRef
64.
Tschoepe D, Spangenberg P, Esser J, Schwippert B, Kehrel B, Roesen P, Gries FA. Flow-cytometric detection of surface membrane alterations and concommitant changes in the cytoskeletal actin status of activated platelets. Cytometry. 1990;11:652–6.PubMedCrossRef
65.
Addo JB, Bray PF, Grigoryev D, Faraday N, Goldschmidt- Clermont PJ. Surface recruitment but not activation of integrin aIIbb3 (GP IIb:IIIa) requires a functional actin cytoskeleton. Arterioscl Thromb Vasc Biol. 1995;15:1466–73.PubMedCrossRef
66.
Baj-Krzyworzeka M, Majka M, Pratico D, Ratajczak J, Vilaire G, Kijowski J, Reca R, Janowska-Wieczorek A, Ratajczak MZ. Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Exp Hematol. 2002;30:450–9.PubMedCrossRef
67.
Janowska-Wieczorek A, Wysoczynski M, Kijowski J, Marquez-Curtis L, Machalinski B, Ratajczak J, Ratajczak MZ. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer. 2005;113:752–60.PubMedCrossRef
68.
Clemetson KJ, McGregor JL. Characterization of platelet glycoproteins. In: McIntyre DE, Gordon JL, editors. Characterization of platelet glycoproteins Amsterdam: Elsevier, 1987:1–32.
69.
Kunicki TJ, Newman PJ. The molecular immunology of human platelet proteins. Blood. 1992;80:1386–404.PubMed
70.
JL MG. The role of human platelet membrane receptors in inflammation. In: Joseph M, editor. Immunopharmacology of platelets, handbook of immunopharmacology. New York: Academic Press; 1995. p. 67.
71.
Holme PA, Solum NO, Brosstad F, Pedersen T, Kveine M. Microvesicles bind soluble fibrinogen, adhere to immobilized fibrinogen and coaggregate with platelets. Thromb Haemost. 1998;79:389–94.PubMed
72.
Iwamoto S, Kawasaki T, Kambayashi J, Ariyoshi H, Monden M. Platelet microparticles: a carrier of platelet-activating factor? Biochem Biophys Res Commun. 1996;218:940–4.PubMedCrossRef
73.
Barry OP, FitzGerald GA. Mechanisms of cellular activation by platelet microparticles. Thromb Haemost. 1999;82:794–800.PubMed
74.
Barry OP, Pratico D, Savani RC, FitzGerald GA. Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest. 1998;102:136–44.PubMedPubMedCentralCrossRef
75.
Mickelson JK, Lakkis NM, Villarreal-Levy G, Hughes BJ, Smith CW. Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease? J Am Coll Cardiol. 1996;28:345–53.PubMedCrossRef
76.
Sabatier F, Roux V, Anfosso F, Camoin L, Sampol J, Dignat- George F. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity. Blood. 2002;99:3962–70.PubMedCrossRef
77.
Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci. 2000;19:3365–74.
78.
Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood. 1999;94:3791–9.PubMed
79.
Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol. 2002;3:207–14.PubMedCrossRef
80.
Neumann FJ, Marx N, Gawaz M, Brand K, Ott I, Rokitta C, Sticherling C, Meinl C, May A, Schomig A. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation. 1997;95:2387–94.PubMedCrossRef
81.
Seiki M. Membrane-type 1matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett. 2003;194:1–11.PubMedCrossRef
82.
Jaremo P, Sandberg-Gertzen H. Platelet density and size in inflammatory bowel disease. Thromb Haemost. 1996;75:560–1.PubMed
83.
Nawrocki B, Polette M, Marchand V, Monteau M, Gillery P, Tournier JM, Birembaut P. Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: quantificative and morphological analyses. Int J Cancer. 1997;72:556–64.PubMedCrossRef
84.
Tokuraku M, Sato H, Murakami S, Okada Y, Watanabe Y, Seiki M. Activation of the precursor of gelatinase A/72 kDa type IV collagenase/ MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int J Cancer. 1995;64:355–9.PubMedCrossRef
85.
Hrachovinova I, Cambien B, Hafezi-Moghadam A, Kappelmayer J, Camphausen RT, Widom A, Xia L, Kazazian HH. Jr, Schaub RG, McEver RP, Wagner DD. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat Med 2003;9:1020–1025.
86.
Salaj P, Marinov I, Markova M, Pohlreich D, Cetkovsky P, Hrachovinova I. Thrombelastography monitoring of platelet substitution therapy and rFVIIa administration in haemato-oncological patients with severe thrombocytopenia. Prague Med Rep. 2004;105:311–7.PubMed
87.
Iannacone M, Sitia G, Isogawa M, Marchese P, Castro MG, Lowenstein PR, Chisari FV, Ruggeri ZM, Guidotti LG. Platelets mediate cytotoxic T lymphocyte–induced liver damage. Nat Med. 2005;11:1167–9.PubMedPubMedCentralCrossRef
88.
Tao J. Effects of cyclic AMP, cyclic GMP, and protein kinase C on calcium homeostasis and mobilization in normal and thrombotic platelets. Ph.D. Thesis, Univ. of Miami, Coral Gables, FL, 1994.
89.
Opartkiattikul N, Funahara T, Hijikata-Okonomiya A, Yamaguchi N, Talad P. Development of a new method for detection of platelet factor 3 like activity. Southeast Asian J Trop Med Public Health. 1992;23(Suppl 2):47–51.PubMed
90.
Behnke O, Forer A. Blood platelet heterogeneity: evidence for two classes of platelets in man and rat. Br J Haematol. 1993;84:686–93.PubMedCrossRef
91.
Hijikata-Okunomiya A. A new method for the determination of prothrombine in human plasma. Thromb Res 1990;57:705–715.
92.
Frojmovic M, Wong T. Dynamic measurements of the platelet membrane glycoprotein IIb-IIIa receptor for fibrinogen by flow cytometry: II. Platelet size-dependent subpopulations. Biophys J. 1991;59:828–37.PubMedPubMedCentralCrossRef
93.
English D, Welch Z, Kovala AT, Harvey K, Volpert OV, Brindley DN, Garcia JG. Sphingosine 1-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis. FASEB J. 2000;14:2255–65.PubMedCrossRef
94.
Rozmyslowicz T, Majka M, Kijowski J, Murphy SL, Conover DO, Poncz M, Ratajczak J, Gaulton GN, Ratajczak MZ. Platelet and megakaryocyte-derived microparticles transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to infection by X4- HIV. AIDS. 2003;17:33–42.PubMedCrossRef
95.
Baj-Krzyworzeka M, Szatanek R, Węglarczyk K, Baran J, Zembala M. Tumour-derived microvesicles modulate biological activity of human monocytes. Immunol Lett. 2007;113:76–82.PubMedCrossRef
96.
Wysoczynski M, Ratajczak MZ. Lung cancer secreted microvesicles: underappreciated modulators of microenvironment in expanding tumors. Int J Cancer. 2009;125:1595–160.PubMedPubMedCentralCrossRef
97.
Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, Baran J, Urbanowicz B, Brański P, Ratajczak MZ, Zembala M. Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer Immunol Immunother. 2006;55:808–18.PubMedCrossRef
98.
Camussi G, Deregibus MC, Bruno S, Grange C, Fonsato V, Tetta C. Exosome/microvesicle-mediated epigenetic reprogramming of cells. Am J Cancer Res. 2011;1:98–110.PubMed
99.
Meckes DG Jr, Raab-Traub N. Microvesicles and viral infection. J Virol 2011;85:12844–12854.
100.
Robertson C, Booth SA, Beniac DR, Coulthart MB, Booth TF, McNicol A. Cellular prion protein is released on exosomes from activated platelets. Blood. 2006;107:3907–11.PubMedCrossRef
101.
Rozmyslowicz T, Majka M, Kijowski J, Gaulton G, Ratajczak M.Z. A new role of platelet – and megakaryocyte-derived microparticles (MP) in HIV infection. Blood 2001;98:786a.
102.
Mack M, Kleinschmidt A, Bruhl H, et al. Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles. A mechanism for cellular human immunodeficiency virus 1 infection. Nat Med. 2000;6:769–75.PubMedCrossRef
103.
Fritzsching B, Schwer B, Kartenbeck J, et al. Release and intercellular transfer of cell surface CD81 via microparticles. J Immunol. 2002;169:5531–7.PubMedCrossRef
104.
Admyre C, Johansson SM, Paulie S, Gabrielsson S. Direct exosome stimulation of peripheral human T cells detected by ELISPOT. Eur J Immunol. 2006;36:1772–81.PubMedCrossRef
105.
Werner N, Wassmann S, Ahlers P, Kosiol S, Nickenig G. Circulating CD31+/annexin V+ apoptotic microparticles correlate with coronary endothelial function in patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2006;26:112–6.PubMedCrossRef
106.
Michelson AD, Furman MI. Laboratory markers of platelet activation and their clinical significance. Curr Opin Hematol. 1999;6:342–8.PubMedCrossRef
107.
Sprague DL, Elzey BD, Crist SA, Waldschmidt TJ, Jensen RJ, Ratliff TL. Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles. Blood. 2008;111:5028–36.PubMedPubMedCentralCrossRef
108.
Distler JH, Pisetsky DS, Huber LC, Kalden JR, Gay S, Distler O. Microparticles as regulators of inflammation: novel players of cellular crosstalk in the rheumatic diseases. Arthritis Rheum. 2005;52:3337–48.PubMedCrossRef
109.
Forlow SB, McEver RP, Nollert MU. Leukocyte-leukocyte interactions mediated by platelet microparticles under flow. Blood. 2000;95:1317–23.PubMed
110.
Giusti I, D’Ascenzo S, Millimaggi D, Taraboletti G, Carta G, Franceschini N, Pavan A, Dolo V. Cathepsin B mediates the pH-dependent proinvasive activity of tumor-shed microvesicles. Neoplasia. 2008;10:481–8.PubMedPubMedCentralCrossRef
111.
English D, Garcia JGN, Brindley DN. Platelet-released phospholipids link haemostasis and angiogenesis. Cardiovasc Res. 2001.
112.
Barry OP, Kazanietz MG, Pratico D, FitzGerald GA. Arachidonic acid in platelet microparticles up-regulates cyclooxygenase-2- dependent prostaglandin formation via a protein kinase C/ mitogen-activated protein kinase-dependent pathway. J Biol Chem. 1999;274:7545–56.PubMedCrossRef
113.
Brunetti M, Martelli N, Manarini S, Mascetra N, Musiani P, Cerletti C, et al. Polymorphonuclear leukocyte apoptosis is inhibited by platelet-released mediators, role of TGFbeta-1. Thromb Haemost. 2000;84:478–83.PubMed
114.
Bakewell SJ, Nestor P, Prasad S, Tomasson MH, Dowland N, Mehrotra M, Scarborough R, Kanter J, Abe K, Phillips D, Weilbaecher KN. Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci U S A. 2003;100:14205–10.PubMedPubMedCentralCrossRef
115.
Honn KV, Tang DG, Chen YQ. Platelets and cancer metastasis: more than an epiphenomenon. Semin Thromb Hemost. 1992;18:392–415.PubMedCrossRef
116.
McHugh KP, Hodivala-Dilke K, Zheng MH, Namba N, Lam J, Novack D, Feng X, Ross FP, Hynes RO, Teitelbaum SL. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest. 2000;105:433–40.PubMedPubMedCentralCrossRef
117.
Zucker S, Pei D, Cao J, Lopez-Otin C. Membrane type-matrix metalloproteinases (MT-MMP. Curr Top Dev Biol. 2003;54:1–74.PubMedCrossRef
118.
Jansen F, Yang X, Hoyer FF, Paul K, Heiermann N, Becher MU, Abu Hussein N, Kebschull M, Bedorf J, Franklin BS, Latz E, Nickenig G, Werner N. Endothelial microparticle uptake in target cells is annexin I/phosphatidylserine receptor dependent and prevents apoptosis. Arterioscler Thromb Vasc Biol. 2012;32:1925–35.PubMedCrossRef
119.
Wei Y, Nazari-Jahantigh M, Neth P, Weber C, Schober A. MicroRNA- 126, -145, and -155: a therapeutic triad in atherosclerosis? Arterioscler Thromb Vasc Biol. 2013;33:449–54.PubMedCrossRef
120.
Diehl P, Fricke A, Sander L, Stamm J, Bassler N, Htun N, Ziemann M, Helbing T, El-Osta A, Jowett JB, Peter K. Microparticles: major transport vehicles for distinct microRNAs in circulation. Cardiovasc Res. 2012;93:633–44.PubMedPubMedCentralCrossRef
121.
Christianson HC, Svensson KJ, Beltinga M. Exosome and microvesicle mediated phene transfer in mammalian cells. Semin Cancer Biol. 2014;28:31–8.PubMedCrossRef
122.
Corcoran C, Rani S, O’Brien K, O’Neill A, Prencipe M, Sheikh R, et al. Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PLoS One. 2012:7 .e50999
123.
Ciravolo V, Huber V, Ghedini GC, Venturelli E, Bianchi F, Campiglio M, et al. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol. 2012;227:658–67.PubMedCrossRef
124.
Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak J. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci U S A. 2009;106:3794–9.PubMedPubMedCentralCrossRef
125.
Mostefai HA, Andriantsitohaina R, MC M’n. Plasma membrane microparticles in angiogenesis: role in ischemic diseases and in cancer. Physiol Res. 2008;57:311–20.PubMed
126.
Prokopi M, Pula G, Mayr U, Devue C, Gallagher J, Xiao Q, et al. Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures. Blood. 2009;114:723–32.PubMedCrossRef
127.
Brill A, Dashevsky O, Rivo J, Gozal Y, Varon D. Platelet-derived microparticles induce angiogenesis and stimulate post-ischemic revascularization. Cardiovasc Res. 2005;67:30–8.PubMedCrossRef
128.
Martinez MC, Andriantsitohaina R. Microparticles in angiogenesis: therapeutic potential. Circ Res. 2011;109:110–9.PubMedCrossRef
129.
Falanga A, Marchetti M, Vignoli A, Balducci D. Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. Clin Adv Hematol Oncol. 2003;1:673–8.PubMed
130.
van der Meel R1, Fens MH1, Vader P2, van Solinge WW1, Eniola-Adefeso O3, Schiffelers RM4. Extracellular vesicles as drug delivery systems: lessons from the liposome field. J Control Release 2014;195:72–85. doi: 10.​1016/​j.​jconrel.​2014.​07.​049.
131.
Helley D, Banu E, Bouziane A, Banu A, Scotte F, Fischer AM, Oudard S. Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy. Eur Urol. 2009;56:479–84. doi:10.​1016/​j.​eururo.​2008.​06.​038.PubMedCrossRef
132.
Kim HK, Song KS, Park YS, Kang YH, Lee YJ, Lee KR, Ryu KW, Bae JM, Kim S. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer. 2003;39:184–91.PubMedCrossRef
Metadata
Title
The biology of extracellular vesicles with focus on platelet microparticles and their role in cancer development and progression
Authors
M. Żmigrodzka
M. Guzera
A. Miśkiewicz
D. Jagielski
A. Winnicka
Publication date
01-11-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 11/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5358-6

Other articles of this Issue 11/2016

Tumor Biology 11/2016 Go to the issue

Original Article

Endocan reduces the malign grade of gastric cancer cells by regulating associated protein expression

Original Article

Direct targeting of HGF by miR-16 regulates proliferation and migration in gastric cancer

Original Article

Silencing Livin induces apoptotic and autophagic cell death, increasing chemotherapeutic sensitivity to cisplatin of renal carcinoma cells

Original Article

High mucin-7 expression is an independent predictor of adverse clinical outcomes in patients with clear-cell renal cell carcinoma

Review

Regulation of epithelial-mesenchymal transition through microRNAs: clinical and biological significance of microRNAs in breast cancer

Original Article

Novel long non-coding RNA GACAT3 promotes gastric cancer cell proliferation through the IL-6/STAT3 signaling pathway
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits